Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  Galapagos  /  Analyst reports 2019

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

  • 27,180 18 apr 2024 13:50
  • -0,200 (-0,73%) Dagrange 26,940 - 27,300
  • 64.147 Gem. (3M) 80,5K

Analyst reports 2019

382 Posts
Pagina: «« 1 ... 7 8 9 10 11 ... 20 »» | Laatste | Omlaag ↓
  3. avantiavanti 1 augustus 2019 09:33


    Edit: op slide 30, 32 en 33 zie je een aantal woorden die zwartgelakt zijn. Met de PDF-zoekfunctie of door simpelweg de tekst te selecteren/plakken kun je achterhalen dat daar upadacitinib staat. Wat zou de reden zijn dat dit afgeschermd is? Of is het een zoekplaatje om te controleren of de lezer goed opgelet heeft?
    [/quote]

    Waarschijnlijk bang voor een rechtzaak, of ze willen Abbvie niet voor het hoofd stoten omdat ze klant zijn. Veel zoden zet deze blacked out niet aan de dijk, want overduidelijk betreft het idd Upa.
  5. avantiavanti 1 augustus 2019 15:27
    Extract UBS 31 juli 2019

    UBS is weer gestart met Galapagos actief de volgen. Van neutral met TP 91 Euro nu naar BUY met TP 190 Euro.

    Galapagos NV
    More on offer; upgrade to Buy

    Transformative deal not yet fully priced in
    Since the announcement of the deal between Galapagos and Gilead to enter a ten year R&D and commercialisation collaboration ($3.95b cash, $1.1b equity), Galapagos shares have risen 20%. Our new sum of the parts valuation includes updated estimates for key pipeline assets and implies further upside of almost 20%. Reverse engineering the SOTP suggests that the market currently assigns little value to early stage research.
    We believe that this is too conservative and that data for GLPG3312 (Toledo project, see below) in 2H will be a catalyst for some de-risking of this asset and that Gilead's investment increases the likelihood that Galapagos can eventually produce another drug of similar size to current lead asset filgotinib.

    Toledo is generating interest among investors and data is due in 2H
    Galapagos has discovered a novel target in inflammatory disease and is developing several potential drugs which it says show signs of exceptional efficacy as the "Toledo" project. We will see phase I data for the first of these (GLPG3312) in 2H and this should green-light a broad phase II programme starting in 1H20. The target has not yet been revealed (exp. 1H20) but we think initiation of a phase I study for a second compound (GLPG3970) in 2H19 will be taken positively. Gilead's investment is largely seen as a
    vote of confidence in Toledo and developments will be watched closely.

    Filgotinib should see three launches in three years; UBSe sales of $2b in 2026
    After uncertainty around what safety data is needed for submission, expectations are now set for filing before the end of 2019. This should mark the start of a chain of events that will see launches in each of three indications (RA, UC, CD) over the next three years. In line with consensus, we believe this can be a $2b+ drug by 2026.
    Changes to the existing filgotinib agreement with Gilead will also enable Galapagos to gain commercial experience in major markets before a solo European launch of GLPG1690 in IPF in a few years' time.

    Valuation: SOTP based price target of EUR190
    We value Galapagos shares using an NPV sum of the parts approach. We account for
    Gilead's cash input and the dilutive impact of share issuance via the deal.

    Analyst: Laura Sutcliffe
  19. avantiavanti 9 september 2019 09:45
    Samenvatting Morgan Stanley update 8 september 2019

    Large Differentiated Pipeline Headlined By Filgotinib, Resume at OW

    Stock Rating Overweight
    Price Target $200.00

    Matthew Harrison, Connor Meehan, Vikram Purohit

    We resume coverage at OW with a $200 PT. The recent transaction with Gilead provides Galapagos with a strong partner to drive the broad pipeline while building commercial operations in the EU. Filgotinib drives near-term upside while the >$5B cash position provides downside protection.

    Resuming coverage at OW: Galapagos is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics with differentiated modes of action. Galapagos has a series of proprietary and partnered compounds currently in development across a variety of indications, most notably inflammatory diseases. In support and validation of this innovative pipeline, Gilead and Galapagos recently finalized a long-term global R&D collaboration. The deal was valued at ~$5.1Bn, with Gilead paying ~$3.95Bn to Galapagos in cash, along with a ~$1.1Bn equity investment (Gilead now has ~22% ownership). Galapagos stands to gain in a variety of ways; the immediate cash injection will enable management to continue with the development of ongoing clinical and pre-clinical programs, along with providing a means to expand the company's proven target discovery engine (from ~500 to ~1,000 scientists). Additionally, the deal allows Galapagos to leverage Gilead's core competencies, which will aid management in their efforts to deliver an integrated biopharma organization with the ability to efficiently commercialize compounds that have demonstrated success in the clinic. In exchange for the investment, Gilead received opt-in rights for all of Galapagos' programs ex-EU, along with warrants to potentially increase equity ownership in Galapagos to ~30%. Strategically, this transaction grows Gilead's mid-to-late stage pipeline in inflammatory diseases and increases its early stage research engine. Our original full note and the terms of the deal can be found here, and Gilead's press release can be found here.

    We believe Galapagos is well positioned for success following the transaction with Gilead. In addition to the immediate benefits associated with the collaboration, Galapagos has a series of value drivers that we believe are likely to contribute to both short and long-term upside. Among near-term value drivers, the most notable is filgotinib, which is Galapagos' lead product candidate. Filgotinib is a highly selective, orally-administered JAK1 inhibitor that is currently in development for a variety of inflammatory indications. Leading indications include Rheumatoid Arthritis (RA), Ulcerative Collitis (UC), and Crohn's Disease (CD). Notably, when compared to competitors Xeljanz and Olumiant, we believe the drug has best in class efficacy with a cleaner safety profile. With the filing accepted in the EU for RA and on-track for this year in the US, we see continued progress with filgotinib as a key valuation driver. We model ~$550M in US royalties and ~$330M in OUS 2025E profit-split for filgotinib.

    Both proprietary and partnered programs provide near-term catalysts: In addition to filgotinib, Galapagos has a series of other programs, both partnered and proprietary, that represent key value drivers for the company. A summary of these programs, along with the next key catalyst for each, can be found below.

    Upcoming R&D day and Toledo compound disclosure represent additional catalysts: In addition to the assets above, Galapagos is currently developing a class of drugs known as Toledo compounds. The class of drugs is intended to address inflammatory diseases, and though the method of action has yet to be disclosed, management has emphasized continued confidence in the program as a whole. A PhI trial evaluating GLPG3312 (a first generation Toledo compound) began in 2Q19, and we expect initial data in 2020. Notably, the Toledo mechanism has outperformed any other mechanism management has evaluated in preclinical studies for IBD. More broadly, Galapagos intends to host an R&D day on 11/14 which could provide further insight into their pipeline.

    Risk reward is positively skewed as a result of near-term catalysts and cash position. The Gilead transaction, which increased cash to ~60% of the current market cap, provides investors with significant downside protection and a positive risk/reward skew regarding the pipeline. We continue to view filgotinib coupled with continued pipeline execution as the key factors driving GLPG higher.

    Bijlage: Key progranms and next catalysts MS
    Bijlage:
  20. forum rang 4 Wall Street Trader 9 september 2019 11:53
    Thank you avantiavanti for the report.
    Keep them coming!

    Morgan Stanley hervat coverage op de ADR aandelen met een "overweight"-advies en $200 koersdoel (23% opwaarts pot.)
    Gemiddelde ADR-koersdoel bedraagt nu $195.20, obv 12 adviezen (geen enkel sell-advies).

    Pipeline from the Morgan Stanley report.

    Bijlage:
382 Posts
Pagina: «« 1 ... 7 8 9 10 11 ... 20 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Weinig houvast voor beleggers in Galapagos

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Galapagos Nieuws

  1. 12 apr KBC Securities verlaagt koersdoel Galapagos naar 50 euro
  2. 05 apr Galapagos toont innovatieve aanpak in hematologische kankerzorg
  3. 23 feb AEX op de waakvlam het weekend in, koersdreun Besi, Alfen en Galapagos 2
  4. 23 feb Beursblik: gebrek aan opwaarts potentieel voor Galapagos op korte termijn
  5. 23 feb Gaat AEX op recordjacht of gaat de beursweek uit als een nachtkaars?
  6. 23 feb Update : Galapagos voldoet aan verwachtingen
  7. 19 feb Beursblik: cashburn belangrijk voor Galapagos
  8. 15 feb Galapagos presenteert nieuwe onderzoeksdata op EBMT-EHA bijeenkomst
  9. 01 feb Galapagos rondt Jyseleca-transactie af
  10. 04 jan Galapagos in zee met Thermo Fisher

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!